// App-Quantinova.ai

: Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Teresa Alonso Gordoa

Principal Investigators

  • Michael Moses Goodman

  • Christof Vulsteke

  • Guilhem Roubaud

  • Jingsong Zhang

  • Mamta Parikh

  • Josep M. Piulats

  • Analía Azaro

  • Gareth D James

  • Riccardo Cavazzina

  • Eric Gangl

  • Jeff Thompson

  • Gayle Pageau Pouliot

  • Rakesh Kumar

  • Christopher Sweeney

Medical Centers

  • Institut Bergonie, Bordeaux, France

  • Catalan Institute of Oncology, Badalona, Spain

  • BioPharma R&D, AstraZeneca, Boston, MA

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Medical Statistics Consultancy Ltd, London, United Kingdom

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • University of California, San Francisco, CA

  • Integrated Cancer Center in Ghent, Maria Middelares, and Center for Oncological Research (CORE), University of Antwerp, Ghent, Belgium

  • Wake Forest Baptist Health, Winston-Salem, NC

  • Astrazeneca R and D Boston, Waltham, MA

  • AstraZeneca, Gaithersburg, MD

  • Oncology iMED, AstraZeneca, Waltham, MA.

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Belgium

  • France

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • Cabazitaxel

  • Durvalumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • NCT04089553

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved